Jaguar Health, Inc.

Jaguar Health announced the automatic conversion of its Series O Convertible Preferred Stock into common stock at a ratio of 3.209 common shares per preferred share, effective June 25, 2026. This conversion follows the preferred stock being issued as a one-time special stock dividend. Additionally, the company's subsidiary, Napo Pharmaceuticals, amended its Manufacturing and Supply Agreement with Woodward Specialty LLC to clarify inventory management and transfer, ensuring business continuity. Jaguar Health also reiterated its focus on crofelemer development for rare intestinal failure diseases, targeting Breakthrough Therapy designation for MVID and an NDA filing in the first half of 2027.

Jaguar Health's Board of Directors has initiated a process to explore strategic alternatives aimed at maximizing shareholder value. This review is aligned with the anticipated completion of clinical work for a New Drug Application (NDA) filing for its crofelemer-based drug candidate for rare intestinal failure diseases. Potential alternatives include mergers, acquisitions, partnerships, and licensing arrangements. The company emphasizes its commitment to the crofelemer development program, which has shown promising results in clinical trials for conditions like microvillus inclusion disease and short bowel syndrome.

Jaguar Health, Inc. announced that its Board of Directors has initiated a process to explore a range of strategic alternatives aimed at maximizing shareholder value. This exploration aligns with the anticipated completion of clinical work supporting a New Drug Application (NDA) for its crofelemer prescription drug candidate for rare intestinal failure diseases. Potential alternatives include mergers, acquisitions, partnerships, joint ventures, and licensing arrangements. The company highlighted the significant market opportunity for crofelemer, with the microvillus inclusion disease market estimated at $1.1 billion in 2026, projected to reach $1.5 billion by 2033.

Jaguar Health, Inc. has entered into several amendments and exchange agreements primarily with Streeterville Capital, LLC and Uptown Capital, LLC. Key changes include amendments to royalty interest agreements, extending the initiation of monthly royalty payments to October 1, 2026, with a minimum payment of $750,000. Additionally, the maturity date of a $6.22 million promissory note with Streeterville has been extended to October 1, 2026. The company also completed three exchange transactions with Streeterville, issuing a total of 110,249 shares of common stock in exchange for shares of Series Q Preferred Stock.

Jaguar Health, Inc. has entered into a Common Stock Purchase Agreement with an accredited investor, C/M Capital Partners, LP, establishing an Equity Line of Credit (ELOC) for up to $40 million. The agreement allows the company to sell shares of its common stock to the investor under specific terms, including fixed purchases and volume-weighted average price (VWAP) purchases, subject to certain conditions and ownership limitations. The company also agreed to issue $800,000 worth of common stock as Commitment Shares. Stockholder approval for the ELOC has been obtained, enabling potential issuances beyond the initial 19.99% threshold.

Jaguar Health, Inc. announced that all five proposals submitted at its reconvened 2026 Annual Meeting of Stockholders on June 8, 2026, were approved. Key approvals include the election of a Class II director, ratification of RBSM LLP as auditor, and the issuance of more than 19.99% of the company's common stock to C/M Capital Master Fund, LP under two separate agreements. Stockholders also granted the company discretionary authority to adjourn the meeting if needed to secure sufficient votes for certain proposals.

Jaguar Health, Inc. (JAGX) announced two privately negotiated exchange agreements with Streeterville Capital, LLC. In the first agreement on May 26, 2026, the company issued 31,958 shares of common stock in exchange for 3.72 shares of Series Q Preferred Stock. In the second agreement on June 1, 2026, the company issued 32,710 shares of common stock in exchange for 4.2 shares of Series Q Preferred Stock. These exchanges were made in reliance on an exemption from registration under the Securities Act. Additionally, the company reconvened its 2026 Annual Meeting of Stockholders on June 2, 2026, and further adjourned it to June 8, 2026, to allow stockholders more time to review supplemental proxy materials.

Jaguar Health, Inc. announced it has regained compliance with Nasdaq's Bid Price Rule, ensuring its continued listing on The Nasdaq Stock Market LLC. While compliance has been achieved, the Nasdaq Hearings Panel will maintain jurisdiction until September 1, 2026, and the company will be under a mandatory one-year monitoring period until May 26, 2027. During this monitoring period, any future non-compliance with the bid price rule will lead to an immediate delisting determination without the usual grace period. The company also highlighted significant revenue growth in Q1 2026, with an 816% increase over Q1 2025 and a 527% increase over Q4 2025, driven by a US out-license agreement.

Jaguar Health, Inc. completed two privately negotiated exchange agreements with Streeterville Capital, LLC, issuing a total of 54,222 shares of common stock in exchange for 7.96 shares of Series Q Perpetual Preferred Stock. The preferred shares were subsequently cancelled and retired. Additionally, the company adjourned its 2026 Annual Meeting of Stockholders from May 22, 2026, until June 2, 2026, to provide further information to shareholders regarding certain proposals, following discussions with The Nasdaq Stock Market LLC. A supplement to the proxy statement will be filed before the reconvened meeting.

Jaguar Health reported a significant increase in Q1 2026 total net revenue, up 816% year-over-year to $20.27 million, primarily driven by a U.S. licensing agreement for Mytesi and Canalevia-CA1. The company also saw a substantial improvement in income from operations, moving from a loss to a profit, and a reduced net loss. This strategic shift allows Jaguar to focus on crofelemer development for rare-disease intestinal failure indications, despite a decrease in prescription product revenue.